Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer

Breast cancer is the second most common cause of cancer-related deaths worldwide among women. Despite several therapeutic options, 15% of breast cancer patients succumb to the disease owing to tumor relapse and acquired therapy resistance. Particularly in triple-negative breast cancer (TNBC), develo...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Iskit, Sedef, Lieftink, Cor, Halonen, Pasi, Shahrabi, Aida, Possik, Patricia A., Beijersbergen, Roderick L., Peeper, Daniel S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2016
Gaiak:
Priority Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5189992/
https://ncbi.nlm.nih.gov/pubmed/27374095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10230
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak